Hodgkin’s Lymphoma Market

SKU: DMPH2084 | Last Updated On: Nov 29 2021 | No. of Pages: 180 | Available Formats

> Global Hodgkin’s Lymphoma Market Expected to reach at a high CAGR by 2028: DataM Intelligence

Global Hodgkin’s Lymphoma Market is segmented By Therapy (Targeted Therapy, Chemotherapy, Immunotherapy, Others), By Type (Nodular sclerosis Hodgkin lymphoma, Mixed cellularity Hodgkin lymphoma, Lymphocyte-rich Hodgkin lymphoma, Lymphocyte-depleted Hodgkin lymphoma), By Distribution channel (Hospitals, Clinics, Cancer centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2021-2028

 

Market Overview

The Global "Hodgkin’s Lymphoma Market" is expected to grow at a high CAGR during the forecasting period (2021-2028).

Hodgkin's Lymphoma is a lymphoid malignancy of B-cell origin classified into nodular lymphocyte-predominant Hodgkin's Lymphoma (NLPHL) and classical Hodgkin's Lymphoma (cHL). Hodgkin's Lymphoma accounts for 15% of all cancers in young adults globally, out of which cHL accounts for 95% of all HL's. Hodgkin lymphoma is diagnosed most commonly in people in their late 20s or early 30s.

Source: DataM Intelligence Analysis (2019)

Market Dynamics

The major driving forces are rising incidence and mortality rates, the high cure rates, and the extended survival of many people with Hodgkin's Lymphoma.

The rising incidence of Hodgkin's Lymphoma is one of the dominating factors propelling the global Hodgkin's lymphoma market. National Cancer Institute reported that in 2019, it is estimated that there will be 8,110 new cases of Hodgkin lymphoma, and an estimated 1,000 people will die of this disease. Thus, growing incidences of Hodgkin's lymphoma are boosting the Hodgkin's Lymphoma market.

The extended survival of people with Hodgkin's Lymphoma is expected to grow significantly during the forecast period. Immunotherapy is expected to show prolonged survival of the patients. This is owing to the US FDA approvals of certain immunotherapeutic drugs like Seattle genetics’s Brentuximab vedotin (Adcetris) in 2018 for the Hodgkin lymphoma treatment.

However, the high cost of chemotherapy and the onset of adverse effects of the treatment are expected to hamper the market. For instance, adverse effects like cardiovascular disease and second malignancies such as acute leukemia, lymphoma, and solid tumors are likely to occur.

Market Segmentation

The global Hodgkin lymphoma market can be segmented by therapy as chemotherapy, targeted therapy, immunotherapy, etc.

By therapy, targeted therapy is expected to grow at a high rate over the period of forecast. The drugs will stop the growth and spread of cancer cells and limit harm to normal cells. This is owing to the increased number of US FDA approvals of certain monoclonal antibodies in recent years like Seattle genetics’s Rituximab (Rituxan) and checkpoint inhibitors like Merck’s pembrolizumab (Keytruda) in 2018 for the Hodgkin lymphoma treatment.

Immunotherapy is expected to grow at a significant rate over the period of forecast, owing to increased approvals, increasing research and development activities. Immunotherapy drugs can be used as a first-line treatment for Hodgkin lymphoma, or they can be used in combination with other treatments, like chemotherapy. In December 2018, the multicenter clinical trial, led by Catherine Diefenbach, MD, at NYU School of Medicine and its Perlmutter Cancer Center, found that combination immunotherapy (ipilimumab (Yervoy), nivolumab (Opdivo), and brentuximab vedotin (Adcentris)) showed high activity against recurrent Hodgkin lymphoma.

Chemotherapy is expected to account for the significant market share over the period of forecast, which includes ABVD and BEACOPP regimens due to the increased survival rates and high cure rates of people with Hodgkin's Lymphoma.

Source: DataM Intelligence Analysis (2019)

By type, the market is segmented as nodular sclerosis Hodgkin lymphoma or NSCHL, mixed cellularity Hodgkin lymphoma or MCCHL, lymphocyte-rich Hodgkin lymphoma, lymphocyte-depleted Hodgkin lymphoma. Among these, nodular sclerosis is expected to share a significant market share.  The American Cancer Society states that it is a common type of Hodgkin disease in developed countries. It accounts for  7 out of 10 cases. Leukemia & Lymphoma Society said that it accounts for 70 % of classical Hodgkin lymphoma cases.

The global Hodgkin’s lymphoma market is segmented into hospitals, clinics, cancer centers, and others by distribution channel. Among these, the hospital segment is expected to grow at a significant rate over the period of forecast. This is owing to the increase in incidences of Hodgkin’s lymphoma cases leading to increased demand for the imaging tests like PET/CT scans. PET/CT scans are commonly used to help the doctors stage Hodgkin’s lymphoma and decide how much treatment should be given. Doctors are even looking at whether PET/CT scans done during the treatment can help them decide if more or less treatment is required.

Geographical Analysis

The Hodgkin lymphoma market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America dominated the global Hodgkin lymphoma market. This is due to the increasing incidence, rising prevalence, and mortality rate of Hodgkin's Lymphoma region reimbursement schemes.  The American Cancer Society, in 2016, reported that Hodgkin lymphoma affected around 5000 men and 3700 women in the US. Also, about 620 men and 430 women died due to Hodgkin lymphoma treatment.  Thus, the increasing incidence of HL has boosted North America's share in the global Hodgkin's lymphoma market.

An increased number of approvals is expected to drive the market. For instance, in 2018, Seattle Genetics, Inc. received the Health Canada approval for supplemental New Drug Submission that expanded the use of Adcetris (brentuximab vedotin) in combination with AVD (Adriamycin, vinblastine, and dacarbazine) chemotherapy in the patients with previously untreated Stage IV Hodgkin lymphoma.

Increased research and development activities in the region are expected to boost the market. For instance, in December 2016, Ohio State University Comprehensive Cancer Center and National Cancer Institute (NCI) performed a clinical trial of Ibrutinib in Combination with Nivolumab in patients suffering from classical Hodgkin’s Lymphoma in the US to study its efficacy. Ibrutinib may block the cancer cell growth by blocking the enzymes responsible for growth, and Nivolumab may prevent cancer cells by targeting different cells. Currently, it's in the second phase of clinical trials. The study involves 17 participants and is estimated to be completed by 2020.

However, over the forecast period (2020-2027), the Asia-Pacific is expected to dominate the Global Hodgkin's Lymphoma market. The rising incidence and high mortality rates of Lymphoma have surged the market's growth in the region. According to the leukemia Foundation, in 2017, around 11923 new cases have been reported in Australia.

The presence of research and development activities in the region is expected to boost the market. For instance, in September 2017, the Chinese PLA General Hospital, a Chinese government organization, commenced a clinical trial of Decitabine combined with SHR – 1210. SHR – 1210 is a monoclonal antibody, while Decitabine is an investigational drug capable of boosting antigen expression. The clinical study is for analyzing the safety and efficacy of the drugs. Currently, it is in phase 3 of clinical trials and is anticipated to be launched by January 2022.

 Source: DataM Intelligence Analysis (2019)

Competitive Landscape

The market is moderately concentrated, with a limited number of key players operating in the global Hodgkin lymphoma market. Seattle Genetics, Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Company, Merck & Co., Inc. F Hoffmann-La Roche, Actinium Pharmaceuticals, Aeterna Zentaris Inc., Affimed Therapeutics Ag, Hospira Inc., and Incyte Corporation are the vendors in the market.

The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of Hodgkin’s lymphoma market globally. For instance,

On March 14, 2017, The US FDA granted approval to pembrolizumab (Keytruda) of Merck and Co., Inc. for treating adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or the patients who relapsed after three or more prior lines of therapy.

On May 17, 2016, The US FDA approved nivolumab (Opdivo), marketed by Bristol-Myers Squibb, to treat classical Hodgkin lymphoma patients who have relapsed or progressed after an autotransplant and brentuximab vedotin.

Why Purchase the Report?

  • Visualize the composition of the global Hodgkin's lymphoma Market across each therapy, type, and distribution channel, highlighting the key commercial assets and players.
  • Identify commercial opportunities in the global Hodgkin's lymphoma Market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the global Hodgkin's lymphoma Market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Type mapping in excel for the key Services of all major market players.

 

The Global Hodgkin’s lymphoma market report would provide approximately 70 market data tables, 63 figures, and 220 pages.

 

Target Audience:

  • Equipment Suppliers/ Buyers
  • Type Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Trending Topics

T-cell-lymphoma Market

Mantle Cell Lymphoma Market

​​​​​​

Table of Contents

  1. Hodgkin’s Lymphoma Market Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Hodgkin’s Lymphoma Market – Market Definition and Overview

  3. Hodgkin’s Lymphoma  Market – Executive Summary

    1. Market Snippet by Therapy
    2. Market Snippet by Type
    3. Market Snippet by Distribution channel
  4. Hodgkin’s Lymphoma Market Dynamics

    1. Market Impacting Factors
      1. Drivers
        1. The rising incidences of Hodgkin’s Lymphoma
        2. The extended survival of Hodgkin’s Lymphoma patients
      2. Restraints
        1. The onset of adverse effects
      3. Opportunity
      4. Impact Analysis
  5. Hodgkin’s Lymphoma Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Regulatory Analysis
    3. Supply Chain Analysis
    4. Pricing Analysis
    5. Unmet Needs
  6. Hodgkin’s Lymphoma Market - By Therapy

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
      2. Market Attractiveness Index, By Therapy Segment
    2. Targeted therapy *
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
    3. Chemotherapy
    4. Immunotherapy
    5. Others
  7. Hodgkin’s Lymphoma Market - By Type

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      2. Market Attractiveness Index, By Type Segment
    2. Nodular sclerosis Hodgkin lymphoma or NSCHL*
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
    3. Mixed cellularity Hodgkin lymphoma or MCCHL
    4. Lymphocyte-rich Hodgkin lymphoma
    5. Lymphocyte-depleted Hodgkin lymphoma
  8. Hodgkin’s Lymphoma Market - By Distribution channel

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
      2. Market Attractiveness Index, By Distribution channel Segment
    2. Hospitals *
      1. Introduction
      2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
    3. Clinics
    4. Cancer centers
    5. Others
  9. Hodgkin’s Lymphoma Market - By Region

    1. Introduction
      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
      2. Market Attractiveness Index, By Region
    2. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. The U.S.
        2. Canada
        3. Mexico
    3. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. The U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    4. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    5. Asia Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    6. The Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution channel
  10. Hodgkin’s Lymphoma Market Competitive Landscape

    1. Competitive Scenario
    2. Market Positioning/Share Analysis
    3. Mergers and Acquisitions Analysis
  11. Global Hodgkin’s Lymphoma Market Company Profiles

    1. Seattle Genetics *
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. Ono Pharmaceutical Co., Ltd.
    3. Bristol-Myers Squibb Company
    4. Merck & Co., Inc.
    5. F Hoffmann-La Roche
    6. Actinium Pharmaceuticals
    7. Aeterna Zentaris Inc.
    8. Hospira Inc
    9. Affimed Therapeutics Ag
    10. Incyte corporation (**List not Exhaustive)
  12. Global Hodgkin’s Lymphoma Market – Premium Insights

  13. Global Hodgkin’s Lymphoma Market – Data-M

    1. Appendix
    2. About Us and Services
    3. Contact Us

List of Tables & Figures

LIST OF TABLES 
TABLE 01 GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, BY THERAPY, 2018, 2022 & 2028 ($ MILLION) 
TABLE 02 GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, BY TYPE, 2018, 2022 & 2028 ($ MILLION) 
TABLE 03 GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, BY DISTRIBUTION CHANNEL, 2018, 2022 & 2028 ($ MILLION) 
TABLE 04 GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, BY REGION, 2018, 2022 & 2028 ($ MILLION) 
TABLE 05 GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, BY COUNTRY, 2018, 2022 & 2028 ($ MILLION) 
TABLE 06 GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, BY THERAPY, 2018, 2022 & 2028 ($ MILLION) 
TABLE 07 GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, BY THERAPY, 2017-2028 ($ MILLION) 
TABLE 08 GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, BY TYPE, 2018, 2022 & 2028 ($ MILLION) 
TABLE 09 GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, BY TYPE, 2017-2028 ($ MILLION) 
TABLE 10 GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, BY DISTRIBUTION CHANNEL, 2018, 2022 & 2028 ($ MILLION) 
TABLE 11 GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, BY DISTRIBUTION CHANNEL, 2017-2028 ($ MILLION) 
TABLE 12 GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, BY REGION, 2018, 2022 & 2028 ($ MILLION) 
TABLE 13 GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, BY REGION, 2017-2028 ($ MILLION) 
TABLE 14 GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, BY COUNTRY, 2018, 2022 & 2028 ($ MILLION) 
TABLE 15 GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, BY COUNTRY, 2017-2028 ($ MILLION) 
TABLE 16 NORTH AMERICA HODGKIN'S LYMPHOMA MARKET VALUE, BY THERAPY, 2017-2028 ($ MILLION) 
TABLE 17 NORTH AMERICA HODGKIN'S LYMPHOMA MARKET VALUE, BY TYPE, 2017-2028 ($ MILLION) 
TABLE 18 NORTH AMERICA HODGKIN'S LYMPHOMA MARKET VALUE, BY DISTRIBUTION CHANNEL, 2017-2028 ($ MILLION) 
TABLE 19 NORTH AMERICA HODGKIN'S LYMPHOMA MARKET VALUE, BY REGION, 2017-2028 ($ MILLION) 
TABLE 20 NORTH AMERICA HODGKIN'S LYMPHOMA MARKET VALUE, BY COUNTRY, 2017-2028 ($ MILLION) 
TABLE 21 SOUTH AMERICA HODGKIN'S LYMPHOMA MARKET VALUE, BY THERAPY, 2017-2028 ($ MILLION) 
TABLE 22 SOUTH AMERICA HODGKIN'S LYMPHOMA MARKET VALUE, BY TYPE, 2017-2028 ($ MILLION) 
TABLE 23 SOUTH AMERICA HODGKIN'S LYMPHOMA MARKET VALUE, BY DISTRIBUTION CHANNEL, 2017-2028 ($ MILLION) 
TABLE 24 SOUTH AMERICA HODGKIN'S LYMPHOMA MARKET VALUE, BY REGION, 2017-2028 ($ MILLION) 
TABLE 25 SOUTH AMERICA HODGKIN'S LYMPHOMA MARKET VALUE, BY COUNTRY, 2017-2028 ($ MILLION) 
TABLE 26 EUROPE HODGKIN'S LYMPHOMA MARKET VALUE, BY THERAPY, 2017-2028 ($ MILLION) 
TABLE 27 EUROPE HODGKIN'S LYMPHOMA MARKET VALUE, BY TYPE, 2017-2028 ($ MILLION) 
TABLE 28 EUROPE HODGKIN'S LYMPHOMA MARKET VALUE, BY DISTRIBUTION CHANNEL, 2017-2028 ($ MILLION) 
TABLE 29 EUROPE HODGKIN'S LYMPHOMA MARKET VALUE, BY REGION, 2017-2028 ($ MILLION) 
TABLE 30 EUROPE HODGKIN'S LYMPHOMA MARKET VALUE, BY COUNTRY, 2017-2028 ($ MILLION) 
TABLE 31 ASIA-PACIFIC HODGKIN'S LYMPHOMA MARKET VALUE, BY THERAPY, 2017-2028 ($ MILLION) 
TABLE 32 ASIA-PACIFIC HODGKIN'S LYMPHOMA MARKET VALUE, BY TYPE, 2017-2028 ($ MILLION) 
TABLE 33 ASIA-PACIFIC HODGKIN'S LYMPHOMA MARKET VALUE, BY DISTRIBUTION CHANNEL, 2017-2028 ($ MILLION) 
TABLE 34 ASIA-PACIFIC HODGKIN'S LYMPHOMA MARKET VALUE, BY REGION, 2017-2028 ($ MILLION) 
TABLE 35 ASIA-PACIFIC HODGKIN'S LYMPHOMA MARKET VALUE, BY COUNTRY, 2017-2028 ($ MILLION) 
TABLE 36 MIDDLE EAST & AFRICA HODGKIN'S LYMPHOMA MARKET VALUE, BY THERAPY, 2017-2028 ($ MILLION) 
TABLE 37 MIDDLE EAST & AFRICA HODGKIN'S LYMPHOMA MARKET VALUE, BY TYPE, 2017-2028 ($ MILLION) 
TABLE 38 MIDDLE EAST & AFRICA HODGKIN'S LYMPHOMA MARKET VALUE, BY DISTRIBUTION CHANNEL, 2017-2028 ($ MILLION) 
TABLE 39 MIDDLE EAST & AFRICA HODGKIN'S LYMPHOMA MARKET VALUE, BY REGION, 2017-2028 ($ MILLION) 
TABLE 40 MIDDLE EAST & AFRICA HODGKIN'S LYMPHOMA MARKET VALUE, BY COUNTRY, 2017-2028 ($ MILLION) 
TABLE 41 SEATTLE GENETICS: OVERVIEW 
TABLE 42 SEATTLE GENETICS: PRODUCT PORTFOLIO 
TABLE 43 SEATTLE GENETICS: KEY DEVELOPMENTS 
TABLE 44 ONO PHARMACEUTICAL CO., LTD.: OVERVIEW 
TABLE 45 ONO PHARMACEUTICAL CO., LTD.: PRODUCT PORTFOLIO 
TABLE 46 ONO PHARMACEUTICAL CO., LTD.: KEY DEVELOPMENTS 
TABLE 47 BRISTOL-MYERS SQUIBB COMPANY: OVERVIEW 
TABLE 48 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO 
TABLE 49 BRISTOL-MYERS SQUIBB COMPANY: KEY DEVELOPMENTS 
TABLE 50 MERCK & CO., INC.: OVERVIEW 
TABLE 51 MERCK & CO., INC.: PRODUCT PORTFOLIO 
TABLE 52 MERCK & CO., INC.: KEY DEVELOPMENTS 
TABLE 53 F HOFFMANN-LA ROCHE: OVERVIEW 
TABLE 54 F HOFFMANN-LA ROCHE: PRODUCT PORTFOLIO 
TABLE 55 F HOFFMANN-LA ROCHE: KEY DEVELOPMENTS 
TABLE 56 ACTINIUM PHARMACEUTICALS: OVERVIEW 
TABLE 57 ACTINIUM PHARMACEUTICALS: PRODUCT PORTFOLIO 
TABLE 58 ACTINIUM PHARMACEUTICALS: KEY DEVELOPMENTS 
TABLE 59 AETERNA ZENTARIS INC.: OVERVIEW 
TABLE 60 AETERNA ZENTARIS INC.: PRODUCT PORTFOLIO 
TABLE 61 AETERNA ZENTARIS INC.: KEY DEVELOPMENTS 
TABLE 62 HOSPIRA INC: OVERVIEW 
TABLE 63 HOSPIRA INC: PRODUCT PORTFOLIO 
TABLE 64 HOSPIRA INC: KEY DEVELOPMENTS 
TABLE 65 AFFIMED THERAPEUTICS AG: OVERVIEW 
TABLE 66 AFFIMED THERAPEUTICS AG: PRODUCT PORTFOLIO 
TABLE 67 AFFIMED THERAPEUTICS AG: KEY DEVELOPMENTS 
TABLE 68 INCYTE CORPORATION: OVERVIEW 
TABLE 69 INCYTE CORPORATION: PRODUCT PORTFOLIO 
TABLE 70 INCYTE CORPORATION: KEY DEVELOPMENTS 


 LIST OF FIGURES   
FIGURE 01 GLOBAL HODGKIN'S LYMPHOMA MARKET SHARE, BY THERAPY, 2018 & 2028 (%)   
FIGURE 02 GLOBAL HODGKIN'S LYMPHOMA MARKET SHARE, BY TYPE, 2018 & 2028 (%)   
FIGURE 03 GLOBAL HODGKIN'S LYMPHOMA MARKET SHARE, BY DISTRIBUTION CHANNEL, 2018 & 2028 (%)   
FIGURE 04 GLOBAL HODGKIN'S LYMPHOMA MARKET SHARE, BY REGION, 2018 & 2028 (%)   
FIGURE 05 GLOBAL HODGKIN'S LYMPHOMA MARKET SHARE, BY COUNTRY, 2018 & 2028 (%)   
FIGURE 06 GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 07 GLOBAL HODGKIN'S LYMPHOMA MARKET Y-O-Y GROWTH, BY THERAPY, 2018-2028 (%)   
FIGURE 08 TARGETED THERAPY: GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 09 IMMUNOTHERAPY: GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 10 CHEMOTHERAPY: GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 11 OTHERS: GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 12 GLOBAL HODGKIN'S LYMPHOMA MARKET Y-O-Y GROWTH, BY TYPE, 2018-2028 (%)   
FIGURE 13 NODULAR SCLEROSIS HODGKIN LYMPHOMA OR NSCHL: GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 14 MIXED CELLULARITY HODGKIN LYMPHOMA OR MCCHL: GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 15 LYMPHOCYTE-RICH HODGKIN LYMPHOMA: GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 16 LYMPHOCYTE-DEPLETED HODGKIN LYMPHOMA: GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 17 GLOBAL HODGKIN'S LYMPHOMA MARKET Y-O-Y GROWTH, BY DISTRIBUTION CHANNEL, 2018-2028 (%)   
FIGURE 18 HOSPITAL: GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 19 CLINICS: GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 20 CANCER CENTERS: GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 21 OTHERS: GLOBAL HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 22 GLOBAL HODGKIN'S LYMPHOMA MARKET Y-O-Y GROWTH, BY REGION, 2018-2028 (%)   
FIGURE 23 GLOBAL HODGKIN'S LYMPHOMA MARKET Y-O-Y GROWTH, BY COUNTRY, 2018-2028 (%)   
FIGURE 24 NORTH AMERICA HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 25 NORTH AMERICA HODGKIN'S LYMPHOMA MARKET SHARE, BY THERAPY, 2018 & 2028 (%)   
FIGURE 26 NORTH AMERICA HODGKIN'S LYMPHOMA MARKET SHARE, BY TYPE, 2018 & 2028 (%)   
FIGURE 27 NORTH AMERICA HODGKIN'S LYMPHOMA MARKET SHARE, BY DISTRIBUTION CHANNEL, 2018 & 2028 (%)   
FIGURE 28 NORTH AMERICA HODGKIN'S LYMPHOMA MARKET SHARE, BY REGION, 2018 & 2028 (%)   
FIGURE 29 NORTH AMERICA HODGKIN'S LYMPHOMA MARKET SHARE, BY COUNTRY, 2018 & 2028 (%)   
FIGURE 30 SOUTH AMERICA HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 31 SOUTH AMERICA HODGKIN'S LYMPHOMA MARKET SHARE, BY THERAPY, 2018 & 2028 (%)   
FIGURE 32 SOUTH AMERICA HODGKIN'S LYMPHOMA MARKET SHARE, BY TYPE, 2018 & 2028 (%)   
FIGURE 33 SOUTH AMERICA HODGKIN'S LYMPHOMA MARKET SHARE, BY DISTRIBUTION CHANNEL, 2018 & 2028 (%)   
FIGURE 34 SOUTH AMERICA HODGKIN'S LYMPHOMA MARKET SHARE, BY REGION, 2018 & 2028 (%)   
FIGURE 35 SOUTH AMERICA HODGKIN'S LYMPHOMA MARKET SHARE, BY COUNTRY, 2018 & 2028 (%)   
FIGURE 36 EUROPE HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 37 EUROPE HODGKIN'S LYMPHOMA MARKET SHARE, BY THERAPY, 2018 & 2028 (%)   
FIGURE 38 EUROPE HODGKIN'S LYMPHOMA MARKET SHARE, BY TYPE, 2018 & 2028 (%)   
FIGURE 39 EUROPE HODGKIN'S LYMPHOMA MARKET SHARE, BY DISTRIBUTION CHANNEL, 2018 & 2028 (%)   
FIGURE 40 EUROPE HODGKIN'S LYMPHOMA MARKET SHARE, BY REGION, 2018 & 2028 (%)   
FIGURE 41 EUROPE HODGKIN'S LYMPHOMA MARKET SHARE, BY COUNTRY, 2018 & 2028 (%)   
FIGURE 42 ASIA-PACIFIC HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 43 ASIA-PACIFIC HODGKIN'S LYMPHOMA MARKET SHARE, BY THERAPY, 2018 & 2028 (%)   
FIGURE 44 ASIA-PACIFIC HODGKIN'S LYMPHOMA MARKET SHARE, BY TYPE, 2018 & 2028 (%)   
FIGURE 45 ASIA-PACIFIC HODGKIN'S LYMPHOMA MARKET SHARE, BY DISTRIBUTION CHANNEL, 2018 & 2028 (%)   
FIGURE 46 ASIA-PACIFIC HODGKIN'S LYMPHOMA MARKET SHARE, BY REGION, 2018 & 2028 (%)   
FIGURE 47 ASIA-PACIFIC HODGKIN'S LYMPHOMA MARKET SHARE, BY COUNTRY, 2018 & 2028 (%)   
FIGURE 48 MIDDLE EAST & AFRICA HODGKIN'S LYMPHOMA MARKET VALUE, 2017-2028 ($ MILLION)   
FIGURE 49 MIDDLE EAST & AFRICA HODGKIN'S LYMPHOMA MARKET SHARE, BY THERAPY, 2018 & 2028 (%)   
FIGURE 50 MIDDLE EAST & AFRICA HODGKIN'S LYMPHOMA MARKET SHARE, BY TYPE, 2018 & 2028 (%)   
FIGURE 51 MIDDLE EAST & AFRICA HODGKIN'S LYMPHOMA MARKET SHARE, BY DISTRIBUTION CHANNEL, 2018 & 2028 (%)   
FIGURE 52 MIDDLE EAST & AFRICA HODGKIN'S LYMPHOMA MARKET SHARE, BY REGION, 2018 & 2028 (%)   
FIGURE 53 MIDDLE EAST & AFRICA HODGKIN'S LYMPHOMA MARKET SHARE, BY COUNTRY, 2018 & 2028 (%)   
FIGURE 54 SEATTLE GENETICS: FINANCIALS   
FIGURE 55 ONO PHARMACEUTICAL CO., LTD.: FINANCIALS   
FIGURE 56 BRISTOL-MYERS SQUIBB COMPANY: FINANCIALS   
FIGURE 57 MERCK & CO., INC.: FINANCIALS   
FIGURE 58 F HOFFMANN-LA ROCHE: FINANCIALS   
FIGURE 59 ACTINIUM PHARMACEUTICALS: FINANCIALS   
FIGURE 60 AETERNA ZENTARIS INC.: FINANCIALS   
FIGURE 61 HOSPIRA INC: FINANCIALS   
FIGURE 62 AFFIMED THERAPEUTICS AG: FINANCIALS   
FIGURE 63 INCYTE CORPORATION: FINANCIALS   
 

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Year-End Offer from
DataM Intelligence

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest